⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 15, 2024Expert Opinion on Drug Safety

Hypercalcemia in children induced by denosumab: a case report and an analysis of the FDA adverse event reporting system database

Yiyu Chen Chuxuan Fang Zhiyong Yang Guosheng Qiu Shuangyi Tang

View Full Paper

Ask AI

Bookmark

Share

Abstract

The potential risks of denosumab on pediatric patients have raised concerns about its safety. This article aims to analyze the adverse effects of denosumab in minors, with a specific focus on hypercalcemia.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e60461b6db643587597469 https://doi.org/10.1080/14740338.2024.2379446

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Rebound hypercalcemia post denosumab therapy in an 8-year-old child: A case report2025
2Severe rebound hypercalcemia following denosumab treatment in a paediatric patient with cervical aneurysmal bone cyst: a case report2024
3Hypercalcemia after denosumab discontinuation in patients with osteoporosis: a systematic review and case reportSystematic Review · 2026 · 4 citations
4Experience with denosumab in the treatment of bone diseases in pediatrics at a tertiary care hospital.2025 · 1 citations
5Metaphyseal band fractures in pediatric patients treated with denosumab2025